|
The Hematologic Malignancies Program encompasses research
regarding
Selected Clinical Research Protocols
Collection of blood and marrow samples (tissue bank and
database)
Phase I study of Velcade plus chemotherapy in acute myelogeneous
leukemia
Phase III study of induction chemotherapy, risk-adapted
intensification therapy followed by immunotherapy vs.
observation in previously untreated AML patients < 60
years of age
Phase I study of sequential cord blood transplants
Faculty
David T. Scadden, MD
Director, Hematologic Malignancies
Karen Ballen, MD
Director, Leukemia Program
Philip Amrein, MD
Eyal Attar, MD
Kenneth Cohen, MD
Bimal Dey, MD
Judith Ferry, MD
David Harmon, MD
Nancy J. Harris, MD
Steven McAfee, MD
David Smith, MD
Thomas R. Spitzer, MD
Ronald (Tak) Takvorian, MD
Nancy Tarbell, MD
|
